| Closed |
S1202 |
Ph III Study of Duloxetine for AI-associated musculoskleteal symptoms for Early Stage BrCa |
5/15/2013 |
10/1/2015 |
100% |
|
Published
|
| Closed |
S1115 |
Rando Phase II of AZD-6244 add MK-2206 vs mFOLFOX in Pts with Met Pancreatic Cancer After Chemo |
8/15/2012 |
5/15/2014 |
100% |
|
Published
|
| Closed |
S1117 |
Rando PII Aza vs. Aza/Len vs. Aza/Vorin for High Risk MDS and CMML |
3/1/2012 |
11/14/2014 |
100% |
|
Published
|
| Closed |
S0927 |
Ph III Omega-3 fatty acid/placebo Breast Cancer |
2/1/2012 |
2/1/2013 |
100% |
|
Published
|
| Closed |
S1119 |
Water Contamination Study |
12/2/2011 |
8/5/2013 |
100% |
|
Published
|
| Closed |
S1108 |
Phase II MLN8237 in Peripheral T-Cell NHL |
10/28/2011 |
6/6/2013 |
100% |
|
Published
|
| Closed |
S1106 |
Randomized Phase II Younger Patients Mantle Cell Lymphoma |
10/1/2011 |
6/26/2013 |
29% |
|
Published
|
| Closed |
S1014 |
Metastatic PCa Suboptimal Response ADT, Abiraterone Acetate, Ph II |
8/9/2011 |
8/1/2013 |
98% |
|
Published
|
| Closed |
S1005 |
Ph II MK-2206 gastric and GEJ |
1/1/2011 |
5/1/2013 |
100% |
|
Published
|
| Closed |
S0925 |
New Hormone-Sensitive Metastatic PCa, Androgen Deprivation +/- IMC-A12, Ph II |
12/15/2010 |
12/1/2012 |
100% |
|
Published
|
| Closed |
S0806 |
Phase I/II DLBCL Vorinostat with R-CHOP |
11/15/2010 |
10/1/2013 |
100% |
|
Published
|
| Closed |
S0933 |
Phase II RO4929097 in Adv Melanoma |
10/28/2010 |
11/15/2011 |
45% |
|
Published
|
| Closed |
S0910 |
Cytarabine/Clofarabine +/- Epratuzumab for Relapsed/Refractory B-cell ALL |
8/15/2010 |
7/1/2012 |
100% |
|
Published
|
| Closed |
S0941 |
Phase II Cholangiocarcinoma with Sorafenib + Erlotinib |
4/15/2010 |
9/15/2011 |
73% |
|
Published
|
| Closed |
S0800 |
ADVANCED: Phase II weekly Nab-Paclitaxel +/- Bevacizumab, Preceded or Followed by AC+PEG-G for Locally Advanced Her-2/Neu Neg Breast Cancer |
4/1/2010 |
10/1/2012 |
100% |
|
Published
|
| Closed |
S0905 |
Ph I / Randomized Ph II Mesothelioma Cediranib |
3/15/2010 |
2/15/2016 |
91% |
|
Published
|
| Closed |
S0904 |
Randomized Ph II Ovarian vandetanib + docetaxel |
3/15/2010 |
8/1/2011 |
99% |
|
Published
|
| Closed |
S0715 |
ALC |
9/15/2009 |
2/1/2011 |
100% |
|
Published
|
| Closed |
S0805 |
Phase II HyperCVAD + Dasatinib with or without Allo SCT for Ph+ ALL |
9/1/2009 |
|
100% |
|
Published
|
| Closed |
S0819 |
Phase III Carbo/Taxol/Bevacizumab +/- Cetuximab in Advanced NSCLC |
7/15/2009 |
5/1/2015 |
78% |
|
Published
|
